IQVIA Holdings Inc. (NYSE:IQV) Stake Reduced by Marathon Asset Management Ltd

Marathon Asset Management Ltd lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 8.9% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 156,984 shares of the medical research company's stock after selling 15,386 shares during the quarter. Marathon Asset Management Ltd owned about 0.09% of IQVIA worth $37,200,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the company. Global Retirement Partners LLC grew its holdings in shares of IQVIA by 1.3% during the 3rd quarter. Global Retirement Partners LLC now owns 10,686 shares of the medical research company's stock worth $2,532,000 after purchasing an additional 138 shares during the period. Good Life Advisors LLC purchased a new stake in shares of IQVIA during the 3rd quarter worth about $443,000. nVerses Capital LLC purchased a new stake in shares of IQVIA during the 3rd quarter worth about $379,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in shares of IQVIA by 20.4% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 5,719 shares of the medical research company's stock worth $1,355,000 after purchasing an additional 968 shares during the period. Finally, Sumitomo Life Insurance Co. grew its holdings in shares of IQVIA by 1.4% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 10,068 shares of the medical research company's stock worth $2,386,000 after purchasing an additional 140 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently commented on IQV shares. Robert W. Baird boosted their price target on IQVIA from $251.00 to $256.00 and gave the stock a "neutral" rating in a research report on Friday, September 20th. Redburn Atlantic started coverage on IQVIA in a research report on Monday. They set a "buy" rating and a $276.00 price target on the stock. Royal Bank of Canada started coverage on IQVIA in a research report on Wednesday, September 4th. They set an "outperform" rating and a $275.00 price target on the stock. Barclays reduced their price target on IQVIA from $275.00 to $260.00 and set an "overweight" rating on the stock in a research report on Tuesday. Finally, Jefferies Financial Group lowered IQVIA from a "buy" rating to a "hold" rating and reduced their price target for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $267.87.

IQVIA Stock Performance

Shares of NYSE IQV traded up $2.72 during trading on Friday, reaching $236.61. The stock had a trading volume of 810,936 shares, compared to its average volume of 1,066,540. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The stock has a market cap of $43.13 billion, a PE ratio of 30.38, a P/E/G ratio of 2.22 and a beta of 1.49. The firm's 50 day moving average price is $239.09 and its two-hundred day moving average price is $231.35.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts' consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the previous year, the business earned $2.22 EPS. The business's quarterly revenue was up 2.3% on a year-over-year basis. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the company's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.